Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer

Andre T. Baron, Elsa M. Cora, Jacqueline M. Lafky, Cecelia H. Boardman, Marites C. Buenafe, Alfred Rademaker, Dachao Liu, David A. Fishman, Karl C. Podratz, Nita Jane Maihle

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic malignancies in the United States, for which risk assessment, screening, and diagnostic tests are needed. We have shown previously that women with stage III/IV EOC have lower serum p110 sEGFR/sErbB1 (Soluble Epidermal Growth Factor Receptor) concentrations than healthy women. Here, we show that serum p110 sEGFR/sErbB1 is the product of a 3-kb EGFR/ERBB1 alternate transcript. We report that serum sEGFR concentrations in stage I/II and stage III/IV EOC patients are significantly lower than in healthy women, and that serum sEGFR concentrations are not associated with disease stage or tumor grade. Logistic regression models show that: (a) lower serum sEGFR concentrations are associated significantly with a greater risk of EOC; (b) the risk associated with lower serum sEGFR concentrations is reduced by older age or menopause; and (c) age- or menopausal status-specific cutoff values for sEGFR concentration are appropriate. Receiver operating characteristic curves indicate that: (a) serum sEGFR concentrations are more effective in discerning stage III/IV than stage I/II EOC cases from healthy women; and (b) sEGFR concentrations have an 89% probability of correctly discerning EOC patients from healthy women when accounting for effect modification by age. By maintaining a test specificity of ∼95% across strata of age or menopausal status with appropriate cutoff values, we observe that sEGFR concentrations are most useful for detecting stage I/II (sensitivity: 64-67%) and stage III/IV (sensitivity: 75-81%) EOC in young, premenopausal women. We conclude that serum sEGFR concentrations warrant additional investigation in the risk assessment, early detection, and/or diagnosis of EOC.

Original languageEnglish (US)
Pages (from-to)103-113
Number of pages11
JournalCancer Epidemiology Biomarkers and Prevention
Volume12
Issue number2
StatePublished - Feb 1 2003
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Biomarkers
Serum
Logistic Models
Ovarian epithelial cancer
Menopause
Routine Diagnostic Tests
ROC Curve
Early Diagnosis
Cause of Death
Neoplasms

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Baron, A. T., Cora, E. M., Lafky, J. M., Boardman, C. H., Buenafe, M. C., Rademaker, A., ... Maihle, N. J. (2003). Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiology Biomarkers and Prevention, 12(2), 103-113.

Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. / Baron, Andre T.; Cora, Elsa M.; Lafky, Jacqueline M.; Boardman, Cecelia H.; Buenafe, Marites C.; Rademaker, Alfred; Liu, Dachao; Fishman, David A.; Podratz, Karl C.; Maihle, Nita Jane.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 12, No. 2, 01.02.2003, p. 103-113.

Research output: Contribution to journalArticle

Baron, AT, Cora, EM, Lafky, JM, Boardman, CH, Buenafe, MC, Rademaker, A, Liu, D, Fishman, DA, Podratz, KC & Maihle, NJ 2003, 'Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer', Cancer Epidemiology Biomarkers and Prevention, vol. 12, no. 2, pp. 103-113.
Baron, Andre T. ; Cora, Elsa M. ; Lafky, Jacqueline M. ; Boardman, Cecelia H. ; Buenafe, Marites C. ; Rademaker, Alfred ; Liu, Dachao ; Fishman, David A. ; Podratz, Karl C. ; Maihle, Nita Jane. / Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. In: Cancer Epidemiology Biomarkers and Prevention. 2003 ; Vol. 12, No. 2. pp. 103-113.
@article{7e6bb9a664be4df29ec48017e850a0a2,
title = "Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer",
abstract = "Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic malignancies in the United States, for which risk assessment, screening, and diagnostic tests are needed. We have shown previously that women with stage III/IV EOC have lower serum p110 sEGFR/sErbB1 (Soluble Epidermal Growth Factor Receptor) concentrations than healthy women. Here, we show that serum p110 sEGFR/sErbB1 is the product of a 3-kb EGFR/ERBB1 alternate transcript. We report that serum sEGFR concentrations in stage I/II and stage III/IV EOC patients are significantly lower than in healthy women, and that serum sEGFR concentrations are not associated with disease stage or tumor grade. Logistic regression models show that: (a) lower serum sEGFR concentrations are associated significantly with a greater risk of EOC; (b) the risk associated with lower serum sEGFR concentrations is reduced by older age or menopause; and (c) age- or menopausal status-specific cutoff values for sEGFR concentration are appropriate. Receiver operating characteristic curves indicate that: (a) serum sEGFR concentrations are more effective in discerning stage III/IV than stage I/II EOC cases from healthy women; and (b) sEGFR concentrations have an 89{\%} probability of correctly discerning EOC patients from healthy women when accounting for effect modification by age. By maintaining a test specificity of ∼95{\%} across strata of age or menopausal status with appropriate cutoff values, we observe that sEGFR concentrations are most useful for detecting stage I/II (sensitivity: 64-67{\%}) and stage III/IV (sensitivity: 75-81{\%}) EOC in young, premenopausal women. We conclude that serum sEGFR concentrations warrant additional investigation in the risk assessment, early detection, and/or diagnosis of EOC.",
author = "Baron, {Andre T.} and Cora, {Elsa M.} and Lafky, {Jacqueline M.} and Boardman, {Cecelia H.} and Buenafe, {Marites C.} and Alfred Rademaker and Dachao Liu and Fishman, {David A.} and Podratz, {Karl C.} and Maihle, {Nita Jane}",
year = "2003",
month = "2",
day = "1",
language = "English (US)",
volume = "12",
pages = "103--113",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer

AU - Baron, Andre T.

AU - Cora, Elsa M.

AU - Lafky, Jacqueline M.

AU - Boardman, Cecelia H.

AU - Buenafe, Marites C.

AU - Rademaker, Alfred

AU - Liu, Dachao

AU - Fishman, David A.

AU - Podratz, Karl C.

AU - Maihle, Nita Jane

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic malignancies in the United States, for which risk assessment, screening, and diagnostic tests are needed. We have shown previously that women with stage III/IV EOC have lower serum p110 sEGFR/sErbB1 (Soluble Epidermal Growth Factor Receptor) concentrations than healthy women. Here, we show that serum p110 sEGFR/sErbB1 is the product of a 3-kb EGFR/ERBB1 alternate transcript. We report that serum sEGFR concentrations in stage I/II and stage III/IV EOC patients are significantly lower than in healthy women, and that serum sEGFR concentrations are not associated with disease stage or tumor grade. Logistic regression models show that: (a) lower serum sEGFR concentrations are associated significantly with a greater risk of EOC; (b) the risk associated with lower serum sEGFR concentrations is reduced by older age or menopause; and (c) age- or menopausal status-specific cutoff values for sEGFR concentration are appropriate. Receiver operating characteristic curves indicate that: (a) serum sEGFR concentrations are more effective in discerning stage III/IV than stage I/II EOC cases from healthy women; and (b) sEGFR concentrations have an 89% probability of correctly discerning EOC patients from healthy women when accounting for effect modification by age. By maintaining a test specificity of ∼95% across strata of age or menopausal status with appropriate cutoff values, we observe that sEGFR concentrations are most useful for detecting stage I/II (sensitivity: 64-67%) and stage III/IV (sensitivity: 75-81%) EOC in young, premenopausal women. We conclude that serum sEGFR concentrations warrant additional investigation in the risk assessment, early detection, and/or diagnosis of EOC.

AB - Epithelial ovarian cancer (EOC) is the leading cause of death from gynecologic malignancies in the United States, for which risk assessment, screening, and diagnostic tests are needed. We have shown previously that women with stage III/IV EOC have lower serum p110 sEGFR/sErbB1 (Soluble Epidermal Growth Factor Receptor) concentrations than healthy women. Here, we show that serum p110 sEGFR/sErbB1 is the product of a 3-kb EGFR/ERBB1 alternate transcript. We report that serum sEGFR concentrations in stage I/II and stage III/IV EOC patients are significantly lower than in healthy women, and that serum sEGFR concentrations are not associated with disease stage or tumor grade. Logistic regression models show that: (a) lower serum sEGFR concentrations are associated significantly with a greater risk of EOC; (b) the risk associated with lower serum sEGFR concentrations is reduced by older age or menopause; and (c) age- or menopausal status-specific cutoff values for sEGFR concentration are appropriate. Receiver operating characteristic curves indicate that: (a) serum sEGFR concentrations are more effective in discerning stage III/IV than stage I/II EOC cases from healthy women; and (b) sEGFR concentrations have an 89% probability of correctly discerning EOC patients from healthy women when accounting for effect modification by age. By maintaining a test specificity of ∼95% across strata of age or menopausal status with appropriate cutoff values, we observe that sEGFR concentrations are most useful for detecting stage I/II (sensitivity: 64-67%) and stage III/IV (sensitivity: 75-81%) EOC in young, premenopausal women. We conclude that serum sEGFR concentrations warrant additional investigation in the risk assessment, early detection, and/or diagnosis of EOC.

UR - http://www.scopus.com/inward/record.url?scp=12244261580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244261580&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 103

EP - 113

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 2

ER -